The burden of progressive fibrotic interstitial lung disease across the UK

Almost 15% of new referrals with non-IPF fibrotic ILD go on to develop a progressive fibrotic phenotype and would benefit from antifibrotic therapy https://bit.ly/3uPhClN

Detalles Bibliográficos
Autores principales: Simpson, Thomas, Barratt, Shaney L., Beirne, Paul, Chaudhuri, Nazia, Crawshaw, Anjali, Crowley, Louise E., Fletcher, Sophie, Gibbons, Michael A., Hallchurch, Philippa, Horgan, Laura, Jakaityte, Ieva, Lewis, Thomas, McLellan, Tom, Myall, Katherine J., Miller, Ryan, Smith, David J.F., Stanel, Stefan, Thillai, Muhunthan, Thompson, Fiona, Wallis, Timothy, Wu, Zhe, Molyneaux, Philip L., West, Alex G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264777/
https://www.ncbi.nlm.nih.gov/pubmed/33678609
http://dx.doi.org/10.1183/13993003.00221-2021
Descripción
Sumario:Almost 15% of new referrals with non-IPF fibrotic ILD go on to develop a progressive fibrotic phenotype and would benefit from antifibrotic therapy https://bit.ly/3uPhClN

Ejemplares similares